Share Price and Basic Stock Data
Last Updated: February 6, 2026, 2:41 pm
| PEG Ratio | 0.48 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dishman Carbogen Amcis Ltd operates in the pharmaceuticals sector, reported a market capitalization of ₹3,400 Cr and a share price of ₹216. The company has shown a revenue growth trend, with sales increasing from ₹2,141 Cr in March 2022 to ₹2,413 Cr in March 2023, and further rising to ₹2,616 Cr in March 2024. The trailing twelve months (TTM) revenue stood at ₹2,759 Cr, indicating a positive trajectory. Quarterly revenue figures also reflect fluctuations, with the highest quarterly sales recorded at ₹723 Cr in June 2023, while the most recent quarter (September 2023) saw a decline to ₹587 Cr. This volatility suggests sensitivity to market dynamics, typical of the pharmaceutical sector, where product demand can be influenced by regulatory changes and competitive pressures.
Profitability and Efficiency Metrics
Profitability metrics for Dishman Carbogen Amcis indicate mixed performance. The company’s net profit stood at ₹136 Cr for the TTM period, translating to a P/E ratio of 22.7. However, operating profit margins (OPM) fluctuated significantly, peaking at 23% in the most recent reporting period, but reflecting a decline to just 6% in December 2023. The return on equity (ROE) was reported at 0.32%, while return on capital employed (ROCE) stood at 2.42%. The interest coverage ratio (ICR) of 3.08x signifies sufficient earnings to cover interest expenses, yet the company has experienced profitability challenges, evident from the negative net profit in several quarters. Such variability necessitates close monitoring of operational efficiencies and cost management strategies.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dishman Carbogen Amcis reflects a total asset base of ₹9,987 Cr as of March 2025, with borrowings reported at ₹2,559 Cr. The company maintains a healthy reserve of ₹6,334 Cr, supporting its financial stability. The debt-to-equity ratio stood at 0.35, indicating a moderate level of leverage, which is manageable compared to sector norms. The current ratio of 1.14x suggests adequate liquidity to meet short-term obligations. However, the cash conversion cycle (CCC) extended to 577 days, signaling potential inefficiencies in working capital management. Additionally, the price-to-book value ratio of 0.58x indicates that the stock is trading below its book value, potentially presenting an investment opportunity for value-focused investors.
Shareholding Pattern and Investor Confidence
Dishman Carbogen Amcis has a diverse shareholding structure, with promoters holding 59.32% of the equity. Foreign institutional investors (FIIs) accounted for 8.07% of the shareholding, while domestic institutional investors (DIIs) held 1.37%. Public ownership stood at 31.23%, reflecting a stable investor base. Notably, the number of shareholders declined from 61,175 in December 2022 to 49,455 by September 2025, indicating a potential consolidation of ownership. This trend may raise concerns regarding liquidity and market participation. The sustained promoter stake suggests a long-term commitment to the company’s growth, yet the fluctuating institutional interest signals that investor confidence may be influenced by recent financial performance and market conditions.
Outlook, Risks, and Final Insight
The outlook for Dishman Carbogen Amcis presents both opportunities and challenges. Strengths include a solid revenue base with recent growth, a manageable debt level, and substantial reserves that provide a cushion against market volatility. However, risks persist, such as the company’s inconsistent profitability, high cash conversion cycle, and fluctuating operational margins, which may hinder sustainable growth. Moreover, the pharmaceutical sector’s inherent uncertainties, including regulatory changes and competitive pressures, could impact future performance. Stakeholders should closely monitor operational efficiencies and strategic initiatives aimed at enhancing profitability. A focused approach towards improving working capital management could further bolster the company’s financial health and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,540 Cr. | 325 | 479/192 | 74.1 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.0 Cr. | 53.9 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,580.32 Cr | 1,092.87 | 45.82 | 202.24 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 640 | 619 | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 |
| Expenses | 526 | 567 | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 |
| Operating Profit | 114 | 51 | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 |
| OPM % | 18% | 8% | 17% | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% | 16% |
| Other Income | 4 | -39 | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 |
| Interest | 22 | 24 | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 |
| Depreciation | 50 | 76 | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 |
| Profit before tax | 46 | -88 | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 |
| Tax % | -3% | -19% | 42% | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% | -114% | 24% |
| Net Profit | 47 | -71 | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 | -13 |
| EPS in Rs | 3.00 | -4.51 | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 |
Last Updated: February 6, 2026, 4:16 am
Below is a detailed analysis of the quarterly data for Dishman Carbogen Amcis Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 720.00 Cr.. The value appears strong and on an upward trend. It has increased from 653.00 Cr. (Sep 2025) to 720.00 Cr., marking an increase of 67.00 Cr..
- For Expenses, as of Dec 2025, the value is 607.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 504.00 Cr. (Sep 2025) to 607.00 Cr., marking an increase of 103.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 113.00 Cr.. The value appears to be declining and may need further review. It has decreased from 149.00 Cr. (Sep 2025) to 113.00 Cr., marking a decrease of 36.00 Cr..
- For OPM %, as of Dec 2025, the value is 16.00%. The value appears to be declining and may need further review. It has decreased from 23.00% (Sep 2025) to 16.00%, marking a decrease of 7.00%.
- For Other Income, as of Dec 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Sep 2025) to 7.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Dec 2025, the value is 46.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 42.00 Cr. (Sep 2025) to 46.00 Cr., marking an increase of 4.00 Cr..
- For Depreciation, as of Dec 2025, the value is 84.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 84.00 Cr..
- For Profit before tax, as of Dec 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 31.00 Cr. (Sep 2025) to -10.00 Cr., marking a decrease of 41.00 Cr..
- For Tax %, as of Dec 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from -114.00% (Sep 2025) to 24.00%, marking an increase of 138.00%.
- For Net Profit, as of Dec 2025, the value is -13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 65.00 Cr. (Sep 2025) to -13.00 Cr., marking a decrease of 78.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is -0.83. The value appears to be declining and may need further review. It has decreased from 4.16 (Sep 2025) to -0.83, marking a decrease of 4.99.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:26 am
| Metric | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,759 |
| Expenses | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,243 | 2,177 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 582 |
| OPM % | 20% | 26% | 26% | 27% | 25% | 14% | 15% | 14% | 11% | 17% | 21% |
| Other Income | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 4 | 34 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 176 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 317 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 124 |
| Tax % | 12% | 33% | 33% | 32% | 20% | 154% | -524% | -45% | 26% | 83% | |
| Net Profit | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 136 |
| EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 8.70 | ||
| Dividend Payout % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.90% | 35.48% | -24.29% | -203.77% | 110.91% | -266.67% | -410.00% | 101.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | 28.59% | -59.77% | -179.49% | 314.68% | -377.58% | -143.33% | 511.96% |
Dishman Carbogen Amcis Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 8% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 150% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 31% |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:05 am
Balance Sheet
Last Updated: December 10, 2025, 2:36 am
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 0.00 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 863 | 4,814 | 5,075 | 5,347 | 5,684 | 5,667 | 5,518 | 5,778 | 5,596 | 5,800 | 6,334 |
| Borrowings | 868 | 950 | 1,095 | 1,042 | 1,357 | 1,589 | 1,830 | 2,209 | 2,313 | 2,389 | 2,559 |
| Other Liabilities | 334 | 811 | 967 | 899 | 1,121 | 1,068 | 1,255 | 1,421 | 1,631 | 1,766 | 2,185 |
| Total Liabilities | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,109 |
| Fixed Assets | 1,012 | 4,852 | 5,066 | 5,098 | 5,678 | 5,698 | 5,773 | 6,188 | 6,724 | 7,055 | 7,954 |
| CWIP | 307 | 133 | 151 | 175 | 234 | 486 | 780 | 1,043 | 646 | 467 | 309 |
| Investments | 1 | 40 | 196 | 167 | 191 | 172 | 324 | 249 | 102 | 97 | 91 |
| Other Assets | 761 | 1,550 | 1,757 | 1,881 | 2,091 | 2,000 | 1,758 | 1,959 | 2,098 | 2,368 | 2,756 |
| Total Assets | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,109 |
Below is a detailed analysis of the balance sheet data for Dishman Carbogen Amcis Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
- For Reserves, as of Sep 2025, the value is 6,334.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,800.00 Cr. (Mar 2025) to 6,334.00 Cr., marking an increase of 534.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,559.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,389.00 Cr. (Mar 2025) to 2,559.00 Cr., marking an increase of 170.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,185.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,766.00 Cr. (Mar 2025) to 2,185.00 Cr., marking an increase of 419.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 11,109.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,987.00 Cr. (Mar 2025) to 11,109.00 Cr., marking an increase of 1,122.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,954.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,055.00 Cr. (Mar 2025) to 7,954.00 Cr., marking an increase of 899.00 Cr..
- For CWIP, as of Sep 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 467.00 Cr. (Mar 2025) to 309.00 Cr., marking a decrease of 158.00 Cr..
- For Investments, as of Sep 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,756.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,368.00 Cr. (Mar 2025) to 2,756.00 Cr., marking an increase of 388.00 Cr..
- For Total Assets, as of Sep 2025, the value is 11,109.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,987.00 Cr. (Mar 2025) to 11,109.00 Cr., marking an increase of 1,122.00 Cr..
Notably, the Reserves (6,334.00 Cr.) exceed the Borrowings (2,559.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -667.00 | -498.00 | 444.00 | 551.00 | 502.00 | 273.00 | 330.00 | 330.00 | 284.00 | 467.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 61 | 96 | 79 | 103 | 80 | 81 | 89 | 68 | 90 |
| Inventory Days | 272 | 473 | 525 | 496 | 462 | 402 | 526 | 568 | 540 | 655 |
| Days Payable | 172 | 95 | 201 | 176 | 226 | 132 | 158 | 155 | 149 | 168 |
| Cash Conversion Cycle | 160 | 439 | 419 | 399 | 340 | 350 | 449 | 502 | 458 | 577 |
| Working Capital Days | -52 | 35 | 44 | 43 | -10 | -2 | -8 | -37 | -148 | -35 |
| ROCE % | 5% | 6% | 4% | 0% | 1% | 1% | 0% | 2% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HSBC Flexi Cap Fund | 1,476,000 | 0.7 | 36.54 | 2,377,050 | 2025-12-07 05:28:48 | -37.91% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 0.21 | -9.79 | -1.90 | 1.15 | -10.53 |
| Diluted EPS (Rs.) | 0.21 | -9.79 | -1.90 | 1.15 | -10.53 |
| Cash EPS (Rs.) | 18.94 | 10.04 | 16.00 | 20.77 | 9.11 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 371.91 | 358.90 | 370.51 | 353.89 | 363.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 371.91 | 358.90 | 370.51 | 353.89 | 363.44 |
| Revenue From Operations / Share (Rs.) | 172.93 | 166.82 | 153.89 | 136.52 | 121.94 |
| PBDIT / Share (Rs.) | 31.29 | 20.07 | 22.96 | 23.90 | 19.95 |
| PBIT / Share (Rs.) | 12.56 | 0.24 | 5.05 | 4.29 | 0.30 |
| PBT / Share (Rs.) | 1.23 | -7.80 | -3.48 | -0.27 | -4.15 |
| Net Profit / Share (Rs.) | 0.20 | -9.79 | -1.90 | 1.15 | -10.53 |
| NP After MI And SOA / Share (Rs.) | 0.20 | -9.79 | -1.90 | 1.15 | -10.53 |
| PBDIT Margin (%) | 18.09 | 12.03 | 14.91 | 17.50 | 16.35 |
| PBIT Margin (%) | 7.26 | 0.14 | 3.28 | 3.13 | 0.25 |
| PBT Margin (%) | 0.71 | -4.67 | -2.26 | -0.19 | -3.40 |
| Net Profit Margin (%) | 0.11 | -5.86 | -1.23 | 0.84 | -8.63 |
| NP After MI And SOA Margin (%) | 0.11 | -5.86 | -1.23 | 0.84 | -8.63 |
| Return on Networth / Equity (%) | 0.05 | -2.72 | -0.51 | 0.32 | -2.89 |
| Return on Capital Employeed (%) | 2.43 | 0.05 | 1.03 | 0.93 | 0.06 |
| Return On Assets (%) | 0.03 | -1.60 | -0.31 | 0.20 | -1.98 |
| Long Term Debt / Equity (X) | 0.19 | 0.04 | 0.18 | 0.13 | 0.08 |
| Total Debt / Equity (X) | 0.35 | 0.34 | 0.31 | 0.25 | 0.18 |
| Asset Turnover Ratio (%) | 0.27 | 0.27 | 0.26 | 0.04 | 0.03 |
| Current Ratio (X) | 1.14 | 0.75 | 1.07 | 1.29 | 1.33 |
| Quick Ratio (X) | 0.67 | 0.40 | 0.61 | 0.84 | 0.91 |
| Inventory Turnover Ratio (X) | 3.04 | 0.71 | 0.86 | 0.29 | 0.22 |
| Interest Coverage Ratio (X) | 3.08 | 2.62 | 4.20 | 6.60 | 6.57 |
| Interest Coverage Ratio (Post Tax) (X) | 1.13 | -0.22 | 1.21 | 1.57 | -2.00 |
| Enterprise Value (Cr.) | 4988.85 | 5245.26 | 3590.64 | 4151.85 | 2477.79 |
| EV / Net Operating Revenue (X) | 1.84 | 2.01 | 1.49 | 1.94 | 1.30 |
| EV / EBITDA (X) | 10.17 | 16.67 | 9.97 | 11.08 | 7.92 |
| MarketCap / Net Operating Revenue (X) | 1.26 | 1.41 | 0.81 | 1.36 | 0.89 |
| Price / BV (X) | 0.58 | 0.65 | 0.33 | 0.52 | 0.29 |
| Price / Net Operating Revenue (X) | 1.26 | 1.41 | 0.81 | 1.36 | 0.89 |
| EarningsYield | 0.00 | -0.04 | -0.01 | 0.01 | -0.09 |
After reviewing the key financial ratios for Dishman Carbogen Amcis Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has increased from -9.79 (Mar 24) to 0.21, marking an increase of 10.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has increased from -9.79 (Mar 24) to 0.21, marking an increase of 10.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has increased from 10.04 (Mar 24) to 18.94, marking an increase of 8.90.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 371.91. It has increased from 358.90 (Mar 24) to 371.91, marking an increase of 13.01.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 371.91. It has increased from 358.90 (Mar 24) to 371.91, marking an increase of 13.01.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 172.93. It has increased from 166.82 (Mar 24) to 172.93, marking an increase of 6.11.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 31.29. This value is within the healthy range. It has increased from 20.07 (Mar 24) to 31.29, marking an increase of 11.22.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.56. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 12.56, marking an increase of 12.32.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from -7.80 (Mar 24) to 1.23, marking an increase of 9.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has increased from -9.79 (Mar 24) to 0.20, marking an increase of 9.99.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has increased from -9.79 (Mar 24) to 0.20, marking an increase of 9.99.
- For PBDIT Margin (%), as of Mar 25, the value is 18.09. This value is within the healthy range. It has increased from 12.03 (Mar 24) to 18.09, marking an increase of 6.06.
- For PBIT Margin (%), as of Mar 25, the value is 7.26. This value is below the healthy minimum of 10. It has increased from 0.14 (Mar 24) to 7.26, marking an increase of 7.12.
- For PBT Margin (%), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 10. It has increased from -4.67 (Mar 24) to 0.71, marking an increase of 5.38.
- For Net Profit Margin (%), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has increased from -5.86 (Mar 24) to 0.11, marking an increase of 5.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 8. It has increased from -5.86 (Mar 24) to 0.11, marking an increase of 5.97.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 15. It has increased from -2.72 (Mar 24) to 0.05, marking an increase of 2.77.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 10. It has increased from 0.05 (Mar 24) to 2.43, marking an increase of 2.38.
- For Return On Assets (%), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -1.60 (Mar 24) to 0.03, marking an increase of 1.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.19, marking an increase of 0.15.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from 0.34 (Mar 24) to 0.35, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. There is no change compared to the previous period (Mar 24) which recorded 0.27.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has increased from 0.75 (Mar 24) to 1.14, marking an increase of 0.39.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.40 (Mar 24) to 0.67, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.04. This value is below the healthy minimum of 4. It has increased from 0.71 (Mar 24) to 3.04, marking an increase of 2.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.08. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 3.08, marking an increase of 0.46.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 3. It has increased from -0.22 (Mar 24) to 1.13, marking an increase of 1.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,988.85. It has decreased from 5,245.26 (Mar 24) to 4,988.85, marking a decrease of 256.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.84. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.84, marking a decrease of 0.17.
- For EV / EBITDA (X), as of Mar 25, the value is 10.17. This value is within the healthy range. It has decreased from 16.67 (Mar 24) to 10.17, marking a decrease of 6.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has decreased from 1.41 (Mar 24) to 1.26, marking a decrease of 0.15.
- For Price / BV (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 0.65 (Mar 24) to 0.58, marking a decrease of 0.07.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has decreased from 1.41 (Mar 24) to 1.26, marking a decrease of 0.15.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to 0.00, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dishman Carbogen Amcis Ltd:
- Net Profit Margin: 0.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.43% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.05% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24 (Industry average Stock P/E: 45.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.35
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Dishman Corporate House, Ahmedabad Gujarat 380058 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arpit J Vyas | Managing Director |
| Mrs. Deohooti J Vyas | Whole Time Director |
| Mr. Kulin N Shah | Director |
| Mr. Hemantkumar J Bhatt | Director |
| Dr. Margie S Parikh | Director |
| Mr. Maitri K Mehta | Independent Director |
| Mr. Rajendra S Shah | Independent Director |
| Mr. Dhaval R Shah | Additional Director |
FAQ
What is the intrinsic value of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd's intrinsic value (as of 06 February 2026) is ₹38.13 which is 81.12% lower the current market price of ₹202.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,172 Cr. market cap, FY2025-2026 high/low of ₹322/178, reserves of ₹6,334 Cr, and liabilities of ₹11,109 Cr.
What is the Market Cap of Dishman Carbogen Amcis Ltd?
The Market Cap of Dishman Carbogen Amcis Ltd is 3,172 Cr..
What is the current Stock Price of Dishman Carbogen Amcis Ltd as on 06 February 2026?
The current stock price of Dishman Carbogen Amcis Ltd as on 06 February 2026 is ₹202.
What is the High / Low of Dishman Carbogen Amcis Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dishman Carbogen Amcis Ltd stocks is ₹322/178.
What is the Stock P/E of Dishman Carbogen Amcis Ltd?
The Stock P/E of Dishman Carbogen Amcis Ltd is 24.0.
What is the Book Value of Dishman Carbogen Amcis Ltd?
The Book Value of Dishman Carbogen Amcis Ltd is 406.
What is the Dividend Yield of Dishman Carbogen Amcis Ltd?
The Dividend Yield of Dishman Carbogen Amcis Ltd is 0.00 %.
What is the ROCE of Dishman Carbogen Amcis Ltd?
The ROCE of Dishman Carbogen Amcis Ltd is 2.42 %.
What is the ROE of Dishman Carbogen Amcis Ltd?
The ROE of Dishman Carbogen Amcis Ltd is 0.32 %.
What is the Face Value of Dishman Carbogen Amcis Ltd?
The Face Value of Dishman Carbogen Amcis Ltd is 2.00.